摘要
目的探讨脑胶质瘤疫苗的临床效果。方法将切除下来的脑胶质瘤制成肿瘤组织匀浆,超低温保存,备用。将54例患者分成3组,每组疫苗的组成各有不同。第1组疫苗为单纯胶质瘤组织匀浆;第2组为胶质瘤组织匀浆加卡介苗(BCG);第3组为树突状细胞(DC)加入胶质瘤组织匀浆共同培养制成DC疫苗加BCG。分别评估每组的疗效。结果 3组中位生存期均高于未用DC,有明显的效果,但第2组优于第1组,第3组优于第2组。结论脑胶质瘤术后均可行肿瘤疫苗治疗,其疗效明显优于单纯手术切除、术后化疗或放疗。
Objective To investigate the clinical effect of brain glioma vaccine. Methods Ho-mogenate made from resected brain gliomas was conserved under ultralow temperature for use. 54 patients were divided into three groups:simple glioma homogenate (group 1);glioma homogenate plus bacilie cal-mette guerin (BCG) (group 2) ;dendritic cells (DC) plus glioma homogenate plus BCG (group 3) . Therapeutic effect of every group was evaluated. Results There was distinction therapeutic effect in all three groups. But the effect in group 2 was better than group 1, and the effect in group 3 was better than in group 2. Conclusion Tumor vaccine therapy can be used after brain glioma operations. The effect of this therapy is much better than simple operation, post-operational chemical therapy or radiotherapy.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2003年第2期139-140,共2页
Chinese Journal of Experimental Surgery
